Advocacy intelligence hub — real-time data for patient organizations
HUMIRA: FDA approved
Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
HUMIRA
(adalimumab)Orphan drugAbbVie, Inc.
12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalim...
Remicade
(infliximab)Orphan drugstandardJanssen Biotech, Inc.
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...